News & Media

Press release
First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Medivir to present at the Stockholm Corporate Finance Life Science Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Medivir to present at the Erik Penser Bank Healthcare Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Pia Baumann takes up her position as Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release Regulatory
Medivir has determined the recommended phase 2 dose for fostrox in combination with Lenvima in HCC

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release Regulatory
MEDIVIR AB – YEAR-END REPORT JANUARY – DECEMBER 2022

Continued strong recruitment in the dose escalation part of the fostrox study.   October – December Financial summary for the quarter...

Read more
Press release
Medivir to present at the Redeye Fight Cancer Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Medivir partner Infex Therapeutics receives FDA QIDP designation

Stockholm, Sweden— Medivir AB (Nasdaq Stockholm: MVIR) announced today that its partner Infex Therapeutics, a leading anti-infectives specialist, has been granted...

Read more